, Volume 13, Issue 2, pp 163–181 | Cite as

Vitamin D and diabetes mellitus

  • Chittari Venkata HarinarayanEmail author


The vitamin D endocrine system in now recognized as subserving a wide range of fundamental biological functions in cell differentiation, inhibition of cell growth as well as immunomodulation. Both forms of immunity, namely adaptive and innate, are regulated by 1,25(OH)2D3. The immune-modulatory properties of vitamin D suggest that it could play a potential therapeutic role in prevention of type 1 diabetes mellitus (T1DM). It is postulated that large doses of vitamin D supplementation may influence the pattern of immune regulation and subsequent progression to T1DM in a genetically susceptible individual. More studies are required to substantiate the relation between T1DM and vitamin D/vitamin D analogues in the pattern of immune regulations in susceptible individuals. In type 2 diabetes mellitus (T2DM), vitamin D may influence both insulin secretion and sensitivity. An inverse relationship between T2DM and vitamin D is postulated from cross-sectional and prospective studies, though conclusive proof is as yet lacking. Available studies differ in their design and in the recommended daily allowances (RDA) of vitamin D in non-skeletal diseases and β-cell function. Large, well designed, controlled, randomized interventional studies on the potential role of vitamin D and calcium in prevention and management of T2DM are required to clarify the relationship between vitamin D and glucose homeostasis in T2DM.

Key words

β-cell function Immune functions Insulin secretion Insulin sensitivity Type 1 diabetes mellitus Type 2 diabetes mellitus Vitamin D 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Chagas CE, Borges MC, Martini LA, Rogero MM, 2012 Focus on vitamin D, inflammation and type 2 diabetes. Nutrients 4: 52–67.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    IDF diabetes atlas. International Diabetes Federation 2009 Available at: the-global-burden last accessed on 30/09/2012.
  3. 3.
    Reichrath J, 2007 Exp Dermatol 16: 618–625.PubMedCrossRefGoogle Scholar
  4. 4.
    Holick MF, 2004 Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79: 362–371.PubMedCrossRefGoogle Scholar
  5. 5.
    Webb AR, Kline L, Holick MF, 1988 Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 67: 373–378.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Bikle DD, Pillai S, Gee E, Hincenbergs M, 1985 Regulation of 1,25-dihydroxyvitamin D production in human keratinocytes by interferon-gamma. Endocrinology 124: 655–660.CrossRefGoogle Scholar
  7. 7.
    Ohyama Y, Ozono K, Uchida M, et al, 1996 Functional assessment of two vitamin D-responsive elements in the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 271: 30381–30385.PubMedCrossRefGoogle Scholar
  8. 8.
    DeLuca HF, 2004 Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 80: Suppl 6: 1689–1696.CrossRefGoogle Scholar
  9. 9.
    McKenna NJ, Lanz RB, O’Malley BW, 1999 Nuclear receptor coregulators: cellular and molecular biology. Endocr Rev 20: 321–344.PubMedGoogle Scholar
  10. 10.
    Razani B, Woodman SE, Lisanti MP, 2002 Caveolae: from cell biology to animal physiology. Pharmacol Rev 54: 431–467.PubMedCrossRefGoogle Scholar
  11. 11.
    Prosser DE, Jones G, 2004 Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 29: 664–673.PubMedCrossRefGoogle Scholar
  12. 12.
    Takiishi T, Gysemans C, Bouillon R, Mathieu C, 2010 Vitamin D and diabetes. Endocrinol Metab Clin North Am 39: 419–446.PubMedCrossRefGoogle Scholar
  13. 13.
    Bikle DD, 2009 Extra renal synthesis of 1,25 dihydroxy vitamin D and its health implications. Clin Rev Bone Miner Metab 7: 114–125.CrossRefGoogle Scholar
  14. 14.
    Nishimura A, Shinki T, Jin CH, et al, 1994 Regulation of messenger ribonucleic acid expression of 1 alpha,25-dihydroxyvitamin D3-24-hydroxylase in rat osteoblasts. Endocrinology 134: 794–1799.CrossRefGoogle Scholar
  15. 15.
    Schauber J, Dorschner RA, Coda AB, et al, 2007 Injury enhances TLR2 function and antimicrobial peptide expression through a vitamin D-dependent mechanism. J Clin Invest 117: 803–811.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Nagpal S, Na S, Rathnachalam R, 2005 Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 26: 662–687.PubMedCrossRefGoogle Scholar
  17. 17.
    Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE, 2007 Modulatory effects of 1,25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 179: 1634–1647.PubMedCrossRefGoogle Scholar
  18. 18.
    Bikle DD, 2009 Vitamin D and immune function: Understanding common pathways. Curr Osteoporos Rep 7: 58–63.PubMedCrossRefGoogle Scholar
  19. 19.
    Tanaka H, Abe E, Miyaura C, Shiina Y, Suda T, 1983 1-alpha,25-dihydroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytes. Biochem Biophys Res Commun 117: 86–92.PubMedCrossRefGoogle Scholar
  20. 20.
    Liu PT, Stenger S, Li H, et al, 2006 Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311: 1770–1773.PubMedCrossRefGoogle Scholar
  21. 21.
    Liu YJ, 2005 IPC: professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23: 275–306.PubMedCrossRefGoogle Scholar
  22. 22.
    Guery JC, Adorini L, 1995 Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. J Immunol 154: 536–544.PubMedGoogle Scholar
  23. 23.
    Schwartz RH, 1990 A cell culture model for T lymphocyte clonal anergy. Science 248: 1349–1356.PubMedCrossRefGoogle Scholar
  24. 24.
    Penna G, Adorini L, 2000 1-Alpha,25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 164: 2405–2411.PubMedCrossRefGoogle Scholar
  25. 25.
    Sadeghi K, Wessner B, Laggner U, et al, 2006 Vitamin D3 down-regulates monocyte TLR expression and triggers hyporesponsiveness to pathogen-associated molecular patterns. Eur J Immunol 36: 361–371.PubMedCrossRefGoogle Scholar
  26. 26.
    van Halteren AG, Tysma OM, van Etten E, Mathieu C, Roep BO, 2004 1-alpha,25-dihydroxyvitamin D3 or analogue treated dendritic cells modulate human autoreactive T cells via the selective induction of apoptosis. J Autoimmun 23: 233–239.PubMedCrossRefGoogle Scholar
  27. 27.
    Griffin MD, Lutz WH, Phan VA, et al, 2000 Potent inhibition of dendritic cell differentiation and maturation by vitamin D analogs. Biochem Biophys Res Commun 270: 701–708.PubMedCrossRefGoogle Scholar
  28. 28.
    Lemire JM, Adams JS, Sakai R, Jordan SC, 1984 1-alpha,25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Clin Invest 74: 657–661.PubMedPubMedCentralCrossRefGoogle Scholar
  29. 29.
    Mathieu C, Badenhoop K, 2005 Vitamin D and type 1 diabetes mellitus: state of the art. Trends Endocrinol Metab 16: 261–266.PubMedCrossRefGoogle Scholar
  30. 30.
    Spach KM, Nashold FE, Dittel BN, Hayes CE, 2006 IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 177: 6030–6037.PubMedCrossRefGoogle Scholar
  31. 31.
    Iho S, Iwamoto K, Kur AF, Okuno Y, Takahashi T, Hoshino T, 1990 Mechanism in 1,25(OH)2D3-induced suppression of helper/suppressor function of CD4/CD8 cells to immunoglobulin production in B cells. Cell Immunol 127: 12–25.PubMedCrossRefGoogle Scholar
  32. 32.
    Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A, 2001 1alpha,25-Dihydroxyvitamin D3 has a direct effect on naive CD4(1) T cells to enhance the development of Th2 cells. J Immunol 167: 4974–4980.PubMedCrossRefGoogle Scholar
  33. 33.
    Imazeki I, Matsuzaki J, Tsuji K, Nishimura T, 2006 Immunomodulating effect of vitamin D3 derivatives on type-1 cellular immunity. Biomed Res 27: 1–9.PubMedCrossRefGoogle Scholar
  34. 34.
    van Etten E, Mathieu C, 2005 Immunoregulation by 1,25-dihydroxyvitamin D3: basic concepts. J Steroid Biochem Mol Biol 97: 93–101.PubMedCrossRefGoogle Scholar
  35. 35.
    Overbergh L, Decallonne B, Waer M, et al, 2009 1alpha,25-dihydroxyvitamin D3 induces an autoantigen specific T-helper 1/T-helper 2 immune shift in NOD mice immunized with GAD65 (p524–543). Diabetes 49: 1301–1307.CrossRefGoogle Scholar
  36. 36.
    Korn T, Oukka M, Kuchroo V, Bettelli E, 2007 Th17 cells: effector T cells with inflammatory properties. Semin Immunol 19: 362–371.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Atkinson MA, Maclaren NK, 1995 The pathogenesis of insulin-dependent diabetes mellitus. Engl J Med 331: 1428–1436.Google Scholar
  38. 38.
    Foulis AK, McGill M, Farquharson MA, 1991 Insulitis in type 1 (insulin-dependent) diabetes mellitus in man—macrophages, lymphocytes, and interferon-gamma containing cells. J Pathol 165: 97–103.PubMedCrossRefGoogle Scholar
  39. 39.
    Riachy R, Vandewalle B, Belaich S, et al, 2001 Beneficial effect of 1,25 dihydroxyvitamin D3 on cytokine-treated human pancreatic islets. J Endocrinol 169: 161–168.PubMedCrossRefGoogle Scholar
  40. 40.
    Mauricio D, Mandrup-Poulsen T, Nerup J, 1996 Vitamin D analogues in insulin-dependent diabetes mellitus and other autoimmune diseases: a therapeutic perspective. Diabetes Metab Rev 12: 57–68.PubMedCrossRefGoogle Scholar
  41. 41.
    Eizirik DL, Cardozo AK, Cnop M, 2008 The role for endoplasmic reticulum stress in diabetes mellitus. Endocr Rev 29: 42–61.PubMedCrossRefGoogle Scholar
  42. 42.
    Hahn HJ, Kuttler B, Mathieu C, Bouillon R, 1997 1,25-Di-hydroxyvitamin D3 reduces MHC antigen expression on pancreatic beta-cells in vitro. Transplant Proc 29: 2156–2157.PubMedCrossRefGoogle Scholar
  43. 43.
    Riachy R, Vandewalle B, Moerman E, et al, 2006 1,25-Di-hydroxyvitamin D3 protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the Fas receptor. Apoptosis 11: 151–159.PubMedCrossRefGoogle Scholar
  44. 44.
    Mohr SB, Garland CF, Gorham ED, Garland FC, 2008 The association between ultraviolet B irradiance, vitamin D status and incidence rates of type 1 diabetes in 51 regions worldwide. Diabetologia 51: 1391–1398.PubMedCrossRefGoogle Scholar
  45. 45.
    Casteels K, Waer M, Laureys J, et al, 1998 Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Diabetes 51: 1367–1374.Google Scholar
  46. 46.
    Del Pino-Montes J, Benito GE, Fernandez-Salazar MP, et al, 2004 Calcitriol improves streptozotocin-induced diabetes and recovers bone mineral density in diabetic rats. Calcif Tissue Int 75: 526–532.PubMedCrossRefGoogle Scholar
  47. 47.
    Casteels K, Waer M, Laureys J, et al, 1998 Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 65: 1225–1232.PubMedCrossRefGoogle Scholar
  48. 48.
    Zipitis CS, Akobeng AK, 2008 Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis. Arch Dis Child 93: 512–517.PubMedCrossRefGoogle Scholar
  49. 49.
    Vitamin D supplementation in early childhood and risk for Type I (insulin-dependent) diabetes mellitus. The EURODIAB Substudy 2 Study Group 1999 Diabetologia 42: 51–54.CrossRefGoogle Scholar
  50. 50.
    EURODIAB ACE Study Group, 2000 Variation and trends in incidence of childhood diabetes in Europe. Lancet 355: 873–876.CrossRefGoogle Scholar
  51. 51.
    Lorini R, Minicucci L, Napoli F, et al, 2005 Screening for type 1 diabetes genetic risk in newborns of continental Italy. Primary prevention (Prevefin Italy)—preliminary data. Acta Biomed 76(Suppl 3): 31–35.PubMedGoogle Scholar
  52. 52.
    Li X, Liao L, Yan X, et al, 2009 Protective effects of 1-alpha-hydroxyvitamin D3 on residual beta-cell function in patients with adult-onset latent autoimmune diabetes. (LADA). Diabetes Metab Res Rev 25: 411–416.PubMedCrossRefGoogle Scholar
  53. 53.
    Brekke HK, Ludvigsson J, 2007 Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study. Pediatr Diabetes 8: 11–14.PubMedCrossRefGoogle Scholar
  54. 54.
    Bock G, Prietl B, Mader JK, et al, 2011 The effect of vitamin D supplementation on peripheral regulatory T cells and β cell function in healthy humans: a randomized controlled trial. Diabetes Metab Res Rev 27: 942–945.PubMedCrossRefGoogle Scholar
  55. 55.
    Gabbay MA, Sato MN, Finazzo C, Duarte AJ, Dib SA, 2012 Effect of cholecalciferol as adjunctive therapy with insulin on protective immunologic profile and decline of residual β-cell function in new-onset type 1 diabetes mellitus. Arch Pediatr Adolesc Med 166: 601–607.PubMedCrossRefGoogle Scholar
  56. 56.
    Aljabri KS, Bokhari SA, Khan MJ, 2010 Glycemic changes after vitamin D supplementation in patients with type 1 diabetes mellitus and vitamin D deficiency. Ann Saudi Med 30: 454–458.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Bizzarri C, Pitocco D, Napoli N, IMDIAB Group, et al, 2010 No protective effect of calcitriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 33: 1962–1963.PubMedPubMedCentralCrossRefGoogle Scholar
  58. 58.
    Walter M, Kaupper T, Adler K, Foersch J, Bonifacio E, Ziegler AG, 2010 No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 33: 1443–1448.PubMedPubMedCentralCrossRefGoogle Scholar
  59. 59.
    Pitocco D, Crinò A, Di Stasio E, IMDIAB Group, et al, 2006 The effects of calcitriol and nicotinamide on residual pancreatic beta-cell function in patients with recent-onset Type 1 diabetes (IMDIAB XI). Diabet Med 23: 920–923.PubMedCrossRefGoogle Scholar
  60. 60.
    Norman AW, 2006 Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 147: 5542–5548.PubMedCrossRefGoogle Scholar
  61. 61.
    Eliades M, Pittas AG, 2010 Vitamin D and type 2 diabetes. In Vitamin D Physiology, Molecular Biology and clinical applications ed. Holick M F. Humana press: pp, 895–920.Google Scholar
  62. 62.
    Fujita T, Palmieri GM, 2000 Calcium paradox disease: calcium deficiency prompting secondary hyperparathyroidism and cellular calcium overload. J Bone Miner Metab 18: 109–125.PubMedCrossRefGoogle Scholar
  63. 63.
    Fujita T, 2000 Calcium paradox: consequences of calcium deficiency manifested by a wide variety of diseases. J Bone Miner Metab 18: 234–236.PubMedCrossRefGoogle Scholar
  64. 64.
    Dunlop TW, Väisänen S, Frank C, Molnár F, Sinkkonen L, Carlberg C, 2005 The human peroxisome proliferator-activated receptor delta gene is a primary target of 1alpha,25-dihydroxyvitamin D3 and its nuclear receptor. J Mol Biol 349: 248–260.PubMedCrossRefGoogle Scholar
  65. 65.
    Wei Y, Sowers JR, Clark S.E, Li W, Ferrario CM, Stump CS, 2008 Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab 294: E345–351.PubMedCrossRefGoogle Scholar
  66. 66.
    Gregori S, Giarratana N, Smiroldo S, Uskokovic M, Adorini L, 2002 1alpha,25-dihydroxyvitamin D3 analog enhances regulatory T-cells and arrests autoimmune diabetes in NOD mice. Diabetes 51: 1367–1374.PubMedCrossRefGoogle Scholar
  67. 67.
    Chertow BS, Sivitz WI, Baranetsky NG, Cordle MB, DeLuca HF, 1986 Islet insulin release and net calcium retention in vitro in vitamin D-deficient rats. Diabetes 35: 771–775.PubMedCrossRefGoogle Scholar
  68. 68.
    Cade C, Norman AW, 1987 Rapid normalization/stimulation by 1,25-dihydroxyvitamin D3 of insulin secretion and glucose tolerance in the vitamin D-deficient rat. Endocrinology 120: 1490–1497.PubMedCrossRefGoogle Scholar
  69. 69.
    Norman AW, Frankel JB, Heidt AM, Grodsky GM, 1980 Vitamin D deficiency inhibits pancreatic secretion of insulin. Science 209: 823–825.PubMedCrossRefGoogle Scholar
  70. 70.
    Pittas AG, Lau J, Hu FB, Dawson-Hughes B, 2007 The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Metab 92: 2017–2029.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Martins D, Wolf M, Pan D, et al, 2007 Prevalence of cardiovascular risk factors and the serum levels of 25-hydroxyvitamin D in the United States: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 167: 1159–1165.PubMedCrossRefGoogle Scholar
  72. 72.
    Scragg R, Sowers M, Bell C, 2004 Third National Health and Nutrition Examination Survey. Serum 25-hydroxy — vitamin D, diabetes, and ethnicity in the Third National Health and Nutrition Examination Survey. Diabetes Care 27: 2813–2818.PubMedCrossRefGoogle Scholar
  73. 73.
    Hyppönen E, Boucher BJ, Berry DJ, Power C, 2008 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age: a cross-sectional study in the 1958 British Birth Cohort. Diabetes 57: 298–305.PubMedCrossRefGoogle Scholar
  74. 74.
    Chiu KC, Chu A, Go VL, Saad MF, 2004 Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 79: 820–825.PubMedCrossRefGoogle Scholar
  75. 75.
    Alvarez JA, Ashraf A, 2010 Role of vitamin D in insulin secretion and insulin sensitivity for glucose homeostasis. Int J Endocrinol 2010: 351–385.CrossRefGoogle Scholar
  76. 76.
    Need AG, O’Loughlin PD, Horowitz M, Nordin BE, 2005 Relationship between fasting serum glucose, age, body mass index and serum 25 hydroxyvitamin D in postmenopausal women. Clin Endocrinol (Oxf) 62: 738–741.CrossRefGoogle Scholar
  77. 77.
    Liu S, Song Y, Ford ES, Manson JE, Buring JE, Ridker PM, 2005 Dietary calcium, vitamin D, and the prevalence of metabolic syndrome in middle-aged and older U.S. women. Diabetes Care 28: 2926–2932.PubMedCrossRefGoogle Scholar
  78. 78.
    Pittas AG, Dawson-Hughes B, Li T, et al, 2006 Vitamin D and calcium intake in relation to type 2 diabetes in women. Diabetes Care 29: 650–656.PubMedCrossRefGoogle Scholar
  79. 79.
    Knekt P, Laaksonen M, Mattila C, et al, 2008 Serum vitamin D and subsequent occurrence of type 2 diabetes. Epidemiology 19: 666–671.PubMedCrossRefGoogle Scholar
  80. 80.
    Harris SS, Pittas AG, Palermo NJ, 2012 A randomized, placebo-controlled trial of vitamin D supplementation to improve glycaemia in overweight and obese African Americans. Diabetes Obes Metab 14: 789–794.PubMedCrossRefGoogle Scholar
  81. 81.
    Eftekhari MH, Akbarzadeh M, Dabbaghmanesh MH, et al, 2011 Impact of treatment with oral calcitriol on glucose indices in type 2 diabetes mellitus patients. Asia Pac J Clin Nutr 20: 521–526.PubMedGoogle Scholar
  82. 82.
    Mitri J, Dawson-Hughes B, Hu FB, Pittas AG, 2011 Effects of vitamin D and calcium supplementation on pancreatic β cell function, insulin sensitivity, and glycemia in adults at high risk of diabetes: the Calcium and Vitamin D for Diabetes Mellitus (CaDDM) randomized controlled trial. Am J Clin Nutr 94: 486–494.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Nikooyeh B, Neyestani TR, Farvid M, et al, 2011 Daily consumption of vitamin D-or vitamin D + calcium-fortified yogurt drink improved glycemic control in patients with type 2 diabetes: a randomized clinical trial. Am J Clin Nutr 93: 764–771.PubMedCrossRefGoogle Scholar
  84. 84.
    Sabherwal S, Bravis V, Devendra D, 2010 Effect of oral vitamin D and calcium replacement on glycaemic control in South Asian patients with type 2 diabetes. Int J Clin Pract 64: 1084–1089.PubMedCrossRefGoogle Scholar
  85. 85.
    von Hurst PR, Stonehouse W, Coad J, 2010 Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D deficient — a randomized, placebo-controlled trial. Br J Nutr 103: 549–555.CrossRefGoogle Scholar
  86. 86.
    Pittas AG, Harris SS, Stark PC, Dawson-Hughes B, 2007 The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in non-diabetic adults. Diabetes Care 30: 980–986.PubMedCrossRefGoogle Scholar
  87. 87.
    Borissova AM, Tankova T, Kirilov G, Dakovska L, Kovacheva R, 2003 The effect of vitamin D3 on insulin secretion and peripheral insulin sensitivity in type 2 diabetic patients. Int J Clin Pract 57: 258–261.PubMedGoogle Scholar
  88. 88.
    Boucher BJ, Mannan N, Noonan K, Hales CN, Evans SJ, 1995 Glucose intolerance and impairment of insulin secretion in relation to vitamin D deficiency in East London Asians. Diabetologia 38: 1239–1245.PubMedCrossRefGoogle Scholar
  89. 89.
    Orwoll E, Riddle M, Prince M, 1994 Effects of vitamin D on insulin and glucagon secretion in non-insulin-dependent diabetes mellitus. Am J Clin Nutr 59: 1083–1087.PubMedCrossRefGoogle Scholar
  90. 90.
    Inomata S, Kadowaki S, Yamatani T, Fukase M, Fujita T, 1986 Effect of 1α(OH)-vitaminD3 on insulin secretion in diabetes mellitus. Bone Miner 1: 187–192.PubMedGoogle Scholar
  91. 91.
    Gedik O, Akalin S, 1986 Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia 29: 142–145.PubMedCrossRefGoogle Scholar
  92. 92.
    Nyomba BL, Auwerx J, Bormans V, 1986 Pancreatic secretion in man with subclinical vitamin D deficiency. Diabetologia 29: 34–38.PubMedCrossRefGoogle Scholar
  93. 93.
    Witham MD, Dove FJ, Dryburgh M, Sugden JA, Morris AD, Struthers AD, 2010 The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia 53: 2112–2119.PubMedCrossRefGoogle Scholar
  94. 94.
    Jorde R, Sneve M, Torjesen P, Figenschau Y, 2010 No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern 267: 462–472.Google Scholar
  95. 95.
    Patel P, Poretsky L, Liao E, 2010 Lack of effect of subtherapeutic vitamin D treatment on glycemic and lipid parameters in Type 2 diabetes: A pilot prospective randomized trial. J Diabetes 2: 36–40.PubMedCrossRefGoogle Scholar
  96. 96.
    Parekh D, Sarathi V, Shivane VK, Bandgar TR, Menon PS, Shah NS, 2010 Pilot study to evaluate the effect of short-term improvement in vitamin D status on glucose tolerance in patients with type 2 diabetes mellitus. Endoer Pract 16: 600–608.CrossRefGoogle Scholar
  97. 97.
    Avenell A, Cook JA, Maclennan GS, Macpherson GC, RECORD trial group, 2009 Vitamin D supplementation and type 2 diabetes: a substudy of a randomized placebo-controlled trial in older people (RECORD trial, ISRCTN 51647438). Age Ageing 38: 606–609.PubMedCrossRefGoogle Scholar
  98. 98.
    Jorde R, Figenschau Y, 2009 Supplementation with cholecalciferol does not improve glycaemic control in diabetic subjects with normal serum 25-hydroxyvitamin D levels. Eur J Nutr 48: 349–354.PubMedCrossRefGoogle Scholar
  99. 99.
    Nagpal J, Pande JN, Bhartia A, 2009 A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabet Med 26: 19–27.PubMedCrossRefGoogle Scholar
  100. 100.
    Zittermann A, Frisch S, Berthold HK, et al, 2009 Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 89: 1321–1327.PubMedCrossRefGoogle Scholar
  101. 101.
    de Boer IH, Tinker LF, Connelly S, et al, 2008 Women’s Health Initiative Investigators. Calcium plus vitamin D supplementation and the risk of incident diabetes in the Women’s Health Initiative. Diabetes Care 31: 701–707.PubMedPubMedCentralCrossRefGoogle Scholar
  102. 102.
    Tai K, Need AG, Horowitz M, Chapman IM, 2008 Glucose tolerance and vitamin D: effects of treating vitamin D deficiency. Nutrition 24: 950–956.PubMedCrossRefGoogle Scholar
  103. 103.
    Sugden JA, Davies JI, Witham MD, et al, 2008 Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med 25: 320–325.PubMedCrossRefGoogle Scholar
  104. 104.
    Fliser D, Stefanski A, Franek E, Fode P, Gudarzi A, Ritz E, 1997 No effect of calcitriol on insulin-mediated glucose uptake in healthy subjects. Eur J Clin Invest 27: 629–633.PubMedCrossRefGoogle Scholar
  105. 105.
    Zofková I, Stolba P, 1990 Effect of calcitriol and trifluoperazine on glucose stimulated B cell function in healthy humans. Exp Clin Endocrinol 95: 185–191.Google Scholar
  106. 106.
    Lind L, Pollare T, Hvarfner A, Lithell H, Sørensen OH, Ljunghall S, 1989 Long-term treatment with active vitamin D (alphacalcidol) in middle-aged men with impaired glucose tolerance. Effects on insulin secretion and sensitivity, glucose tolerance and blood pressure. Diabetes Res 11: 141–147.PubMedGoogle Scholar
  107. 107.
    Ljunghall S, Lind L, Lithell H, et al, 1987 Treatment with one-alpha-hydroxycholecalciferol in middle-aged men with impaired glucose tolerance. A prospective randomized double-blind study. Acta Med Scand 222: 361–367.PubMedCrossRefGoogle Scholar
  108. 108.
    Nilas L, Christiansen C, 1984 Treatment with vitamin D or its analogues does not change body weight or blood glucose level in postmenopausal women. Int J Obes 8: 407–411.PubMedGoogle Scholar
  109. 109.
    Harinarayan CV, Arvind S, Joshi S, Thennarasu K, Vedavyas V, Baindur A, 2014 Improvement in Pancreatic β Cell Function with Vitamin D and Calcium Supplementation in Vitamin D Deficient Non-Diabetic Subjects. Endocr Pract 20: 129–137.PubMedCrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2014

Authors and Affiliations

  1. 1.Institute of Endocrinology, Diabetes, Thyroid and Osteoporosis DisordersSakra World HospitalsBangaloreIndia

Personalised recommendations